Table V.
Group | Cases | OS (month) | PFS (month) |
---|---|---|---|
Survivin-positive group | 30 | 28.65±7.05 | 19.06±5.04 |
Survivin-negative group | 12 | 39.67±11.24 | 35.88±8.25 |
T-value | 6.25 | 5.87 | |
P-value | <0.05 | <0.05 |
Data are presented as the mean ± standard deviation or n. MM, multiple myeloma; FVADT, fludarabine, vincristine, epirubicin, dexamethasone and thalidomide; OS, overall survival; PFS, progression-free survival.